1229 related articles for article (PubMed ID: 15689168)
21. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
[TBL] [Abstract][Full Text] [Related]
22. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
[TBL] [Abstract][Full Text] [Related]
23. 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist.
Enguehard-Gueiffier C; Hübner H; El Hakmaoui A; Allouchi H; Gmeiner P; Argiolas A; Melis MR; Gueiffier A
J Med Chem; 2006 Jun; 49(13):3938-47. PubMed ID: 16789750
[TBL] [Abstract][Full Text] [Related]
24. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.
Leopoldo M; Berardi F; Colabufo NA; De Giorgio P; Lacivita E; Perrone R; Tortorella V
J Med Chem; 2002 Dec; 45(26):5727-35. PubMed ID: 12477356
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective sigma1 receptor ligands.
Huang Y; Hammond PS; Whirrett BR; Kuhner RJ; Wu L; Childers SR; Mach RH
J Med Chem; 1998 Jun; 41(13):2361-70. PubMed ID: 9632369
[TBL] [Abstract][Full Text] [Related]
26. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
27. Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
van Vliet LA; Tepper PG; Dijkstra D; Damsma G; Wikström H; Pugsley TA; Akunne HC; Heffner TG; Glase SA; Wise LD
J Med Chem; 1996 Oct; 39(21):4233-7. PubMed ID: 8863800
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
29. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.
Unangst PC; Capiris T; Connor DT; Doubleday R; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
J Med Chem; 1997 Dec; 40(25):4026-9. PubMed ID: 9406594
[TBL] [Abstract][Full Text] [Related]
30. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.
Tallman JF; Primus RJ; Brodbeck R; Cornfield L; Meade R; Woodruff K; Ross P; Thurkauf A; Gallager DW
J Pharmacol Exp Ther; 1997 Aug; 282(2):1011-9. PubMed ID: 9262370
[TBL] [Abstract][Full Text] [Related]
31. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
32. First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure.
Leopoldo M; Lacivita E; Colabufo NA; Contino M; Berardi F; Perrone R
J Med Chem; 2005 Dec; 48(25):7919-22. PubMed ID: 16335915
[TBL] [Abstract][Full Text] [Related]
33. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
34. 1-aryl-4-[(5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl]piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.
Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
J Med Chem; 1999 Feb; 42(3):490-6. PubMed ID: 9986719
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.
Leopoldo M; Lacivita E; De Giorgio P; Colabufo NA; Niso M; Berardi F; Perrone R
J Med Chem; 2006 Jan; 49(1):358-65. PubMed ID: 16392820
[TBL] [Abstract][Full Text] [Related]
37. 18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor.
Hocke C; Prante O; Salama I; Hübner H; Löber S; Kuwert T; Gmeiner P
ChemMedChem; 2008 May; 3(5):788-93. PubMed ID: 18306190
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
